Why carry out this study?

The purpose of this study is to investigate biologic use and reasons for switching therapy among patients with non-radiographic axial spondyloarthritis (nr-axSpA) in the United States.

What was learned from the study?

This study suggests that around 60% of nr-axSpA patients in the United States were receiving biologic therapy prior to the approval of certolizumab-pegol.

Switching of biologics is frequent in nr-axSpA patients and is usually due to lack of efficacy, loss or response, and effort to accomplish remission.